Cargando…
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including differen...
Autores principales: | Zanon, D., Musazzi, U.M., Manca, A., De Nicolò, A., D'Avolio, A., Cilurzo, F., Maximova, N., Tomasello, C., Clementi, E., Minghetti, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582040/ https://www.ncbi.nlm.nih.gov/pubmed/33110933 http://dx.doi.org/10.1016/j.dib.2020.106445 |
Ejemplares similares
-
Data on the stability of darunavir/cobicistat suspension after tablet manipulation
por: Zanon, D., et al.
Publicado: (2020) -
Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation
por: Musazzi, U.M., et al.
Publicado: (2020) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010) -
Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020) -
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)